Twitter Facebook LinkedIn YouTube

New Listing: Havn Life Sciences (CSE:HAVN)

Video Platform Video Management Video Solutions Video Player

A biotechnology company, Havn Life is focused on the standardized, quality-controlled extraction of psychoactive compounds from plants and fungi to develop products for use in research, which it plans to supply to third parties for use in clinical trials and for production of natural health products.

Additional Information:

Company: Havn Life Sciences
Website: http://www.havnlife.com
Stock Symbol: CSE: HAVN
Date Published: Sep 8, 2020
Transcript: Available

Video Transcript:

I’m Cassandra Bolinski for Investmentpitch Media

Havn Life Sciences, a psychedelics company, is one of the latest new listings on the Canadian Securities Exchange, trading under the symbol “HAVN”.

A biotechnology company, Havn Life is focused on the standardized, quality-controlled extraction of psychoactive compounds from plants and fungi to develop products for use in research, which it plans to supply to third parties for use in clinical trials and for production of natural health products.

Tim Moore, Co-CEO, stated: "Listing on the Canadian Securities Exchange is an important step in Havn Life's growth within the emerging global psychedelic space. There is a tremendous opportunity to transform and enhance the healthcare and wellness space with psychedelic medicine, and the time is now to lay the foundations for what is likely to be a significant industry. Our multidisciplinary team is focused on laying the groundwork by developing quality controls and methodology for research and the medical supply chain."

With its research facility, Havn Labs, located on the South Campus at The University of British Columbia, Havn Life is a part of a global community taking an active part in supporting research for microdosing therapies in treating mental health disorders utilizing psychedelics.

Working with veterans and thought leaders in the military, Havn Life is developing innovative formulations to support clinical trials addressing PTSD recovery and other trauma related disorders.

Susan Chapelle, Co-CEO, added: "We are currently working on a variety of projects including product formulation of effective microdosing of novel psychoactive compounds as well as the development of a state-of-the-art mycology lab for extraction."

The shares are trading at $0.63.

For more information, please visit the company’s website www.havnlife.com, call 604-359-0060 or email at ir@havnlife.com.

Skanderbeg Capital Advisors has been engaged to provide capital market advisory services and corporate communications.

They can be reached at 604-687-7130 or by email at info@skanderbegcapital.com.

I’m Cassandra Bolinski for Investmentpitch Media